Utilization and outcomes of adjuvant therapy for stage II and III uterine leiomyosarcoma.

MLA

Diggs, Alexandra, et al. “Utilization and Outcomes of Adjuvant Therapy for Stage II and III Uterine Leiomyosarcoma.” Gynecologic Oncology, vol. 166, no. 2, Aug. 2022, pp. 308–16. EBSCOhost, https://doi.org/10.1016/j.ygyno.2022.05.018.

APA

Diggs, A., Sia, T. Y., Huang, Y., Gockley, A., Melamed, A., Khoury-Collado, F., St Clair, C., Hou, J. Y., Hershman, D. L., & Wright, J. D. (2022). Utilization and outcomes of adjuvant therapy for stage II and III uterine leiomyosarcoma. Gynecologic Oncology, 166(2), 308–316. https://doi.org/10.1016/j.ygyno.2022.05.018

Chicago

Diggs, Alexandra, Tiffany Y Sia, Yongmei Huang, Allison Gockley, Alexander Melamed, Fady Khoury-Collado, Caryn St Clair, June Y Hou, Dawn L Hershman, and Jason D Wright. 2022. “Utilization and Outcomes of Adjuvant Therapy for Stage II and III Uterine Leiomyosarcoma.” Gynecologic Oncology 166 (2): 308–16. doi:10.1016/j.ygyno.2022.05.018.